Clinical trials: Primary Open - Angle Glaucoma (POAG)
Primary Open Angle Glaucoma, Pseudoexfoliative Glaucoma
Phacotrabeculotomy Versus CCI+Phaco in Patients With Borderline Control of Intraocular Pressure
The purpose of the study is to determine whether combined cataract and glaucoma surgery (phacotrabeculotomy)is more effective in lowering intraocular pressure than cataract surgery alone in patients with borderline control of…
- Trial name
- NCT00346931
- Testing
- Phacoemulsification, implantation of intraocular lens, Phacoemulsification, Implantation of IOL, trabeculotomy
- Volunteers
- 9 people
- Sponsor
- Medical University of Vienna
Glaucoma
Efficacy and Safety of Travoprost 0.004% Versus Tafluprost 0.0015% in Patients With Primary Open-angle Glaucoma or Ocular Hypertension
The purpose of this study is to assess the safety and efficacy of Travoprost 0.004% and Tafluprost 0.0015% in patients with primary open angle glaucoma or ocular hypertension when both medications are administered in the evening.
- Trial name
- NCT00966940
- Testing
- Travoprost 0.004% ophthalmic solution (TRAVATAN), Tafluprost 0.0015% ophthalmic solution
- Volunteers
- 51 people
- Sponsor
- Alcon Research
Primary Open-angle Glaucoma, Ocular Hypertension
Levobetaxolol Hydrochloride Eye Drops for Treatment of Primary Open-angle Glaucoma or Ocular Hypertension
To evaluate the safety and efficacy of Levobetaxolol in Chinese patients with glaucoma.
- Trial name
- NCT02617459
- Testing
- Levobetaxolol eye drops, Betaxolol eye drops
- Where
- China
- Volunteers
- 366 people
- Sponsor
- Zhaoke (Guangzhou) Ophthalmology Pharmaceutical Ltd.
Primary Open Angle Glaucoma
Post Market Study of the InnFocus MicroShunt
Prospective, multicentric, single arm post market study to gather safety and effectiveness data on the CE Marked InnFocus MicroShunt (MIDI Arrow) device in primary open angle glaucoma patients
- Trial name
- NCT02177123
- Testing
- InnFocus MicroShunt implantation
- Where
- 6 sites in France, Netherlands and 2 more
- Volunteers
- 107 people
- Sponsor
- InnFocus Inc.
Primary Open Angle Glaucoma, Normal Tension Glaucoma
Advanced Glycation End Products as a Biomarker for Accelerated Ageing
Globally primary open angle glaucoma (POAG) affects over 60 million people. The exact pathogenesis of POAG is poorly understood. A significant risk factor for glaucoma is advancing age.
- Conditions
- Primary Open Angle Glaucoma, Normal Tension Glaucoma, Ocular Hypertension
- Trial name
- NCT02863224
- Where
- United Kingdom
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- University of Plymouth
Glaucoma, Primary Open Angle (POAG), Ocular Hypertension
Determination Of Predictive Factors Allowing To An Additional 10% Reduction Of Intra-Ocular Pressure
To determine the predictive factors of a positive response to latanoprost 0.005% / timolol 0.5% fixed combination (defined as a 10% IOP reduction from baseline), after 12 weeks of treatment (age, sex, ethnic origin, patient's…
- Trial name
- PREDICOM (NCT00230763)
- Testing
- GSS questionnaire, IOP, LATANOPROST 0.005% / TIMOLOL 0.5% FIXED COMBINATION
- Where
- 102 sites in France
- Volunteers
- 396 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Ocular Hypertension, Open Angle Glaucoma
Study of INS115644 Ophthalmic Solution in Subjects With Ocular Hypertension or Glaucoma
The purpose of this trial is to evaluate the safety and tolerability of INS115644 Ophthalmic Solution in subjects with bilateral ocular hypertension or early primary open angle glaucoma and to investigate the intraocular pressure…
- Trial name
- NCT00443924
- Testing
- INS115644 Ophthalmic Solution
- Volunteers
- 56 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Open Angle Glaucoma, Ocular Hypertension
Ph2 Placebo-Controlled Study for Safety & Ocular Efficacy of SBI-100 Ophthalmic Emulsion in Pts w/ Elevated Eye Pressure
The goal of this clinical trial is to test in patients with glaucoma and elevated pressure in the eye. The main questions it aims to answer are: • ability to lower pressure in the eye • safety in the eye and the body of patients…
- Trial name
- NCT06144918
- Testing
- SBI-100 Ophthalmic Emulsion, 0.5%, SBI-100 Ophthalmic Emulsion, 1.0%
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Skye Bioscience, Inc.
Primary Open Angle Glaucoma (POAG), Ocular Hypertension (OHT)
REGN22530 for Adults With Primary Open Angle Glaucoma or Ocular Hypertension
This study will test an experimental drug called REGN22530 ("study drug") to see if it can help treat people with primary open angle glaucoma or ocular hypertension.
- Trial name
- BAHAMA (NCT07675824)
- Testing
- REGN22530
- Where
- United States
- Volunteers
- 271 people
- Sponsor
- Regeneron Pharmaceuticals
Primary Open-angle Glaucoma, Ocular Hypertension
A Clinical Study to Evaluate the Efficacy and Safety of CKD-351
The purpose of this study is to evaluate efficacy and safety of CKD-351.
- Trial name
- NCT03762369
- Testing
- CKD-351, Latanoprost, D930
- Where
- South Korea
- Volunteers
- 384 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Ocular Hypertension, Primary Open Angle Glaucoma
A Study of Ganfort Versus Duotrav in Patients With Primary Open Angle Glaucoma or Ocular Hypertension
This is a single-center, cross-over comparison parallel group randomized trial designed to evaluate the efficacy and safety of Ganfort compared to Duotrav for a treatment period of 8 weeks each.
- Trial name
- NCT01168414
- Testing
- Ganfort, Duotrav
- Where
- Malaysia
- Volunteers
- 42 people
- Sponsor
- Ministry of Health, Malaysia
Primary Open Angle Glaucoma
Vision Preservation and Restoration Following a 6 Month Trial of GlaucoCetin
This study is looking at changes in vision and visual function before and after a six month trial of a daily medical food called GlaucoCetin, formulated with ingredients to support and protect the optic nerve cells.
- Trial name
- NCT04784234
- Testing
- GlaucoCetin
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Wills Eye
Glaucoma, Ocular Hypertension
Tolerability, Safety and Efficacy of RKI983 Eye Drops in Subjects With Primary Open Angle Glaucoma and Ocular Hypertension
This study will evaluate the tolerability and safety of RKI983 ophthalmic solution and explore the effect of the compound on intraocular pressure in subjects with ocular hypertension.
- Trial name
- NCT00515424
- Testing
- RKI983
- Where
- 5 sites in United States
- Volunteers
- 90 people
- Sponsor
- Novartis
Primary Open Angle Glaucoma, Primary Open-Angle Glaucoma, Unspecified Eye
Glaucoma Screening Using Dynamic Analysis of Computerized Pupillary Light Reflex Assessment Device
To explore an effective diagnostic tool of glaucoma through the dynamic analysis of computerized pupillary light reflex assessment device (CPLRAD) pupillography based on iris recognition techniques and investigate its feasibility…
- Conditions
- Primary Open Angle Glaucoma, Primary Open-Angle Glaucoma, Unspecified Eye, Primary Open Angle Glaucoma of Both Eyes, Suspect Glaucoma
- Trial name
- NCT04595227
- Testing
- Computerized pupillary light reflex assessment device
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Peking University
Primary Open Angle Glaucoma
Efficacy and Safety of Latanoprost/Timolol for Primary Open Angle Glaucoma
Intraocular pressure (IOP) is the most important modifiable risk factor to prevent and delay progression of glaucoma. IOP reduction has been proven to delay the onset and progression of glaucoma, and uncontrolled IOP is…
- Trial name
- NCT04098861
- Testing
- Latanoprost/Timolol
- Where
- Malaysia
- Volunteers
- 40 people
- Sponsor
- Universiti Kebangsaan Malaysia Medical Centre
Primary Open Angle Glaucoma
Cyclophotocoagulation in Primary Open Angle Glaucoma
The use of Cyclodestruction procedures has been extended to patients with non-refractory glaucoma and good vision. Our aim is to compare the safety and efficacy of three cyclodestructive treatments; High Intensity Focused…
- Trial name
- NCT04430296
- Testing
- Cyclophotocoagulation
- Volunteers
- 78 people
- Sponsor
- Cairo University
Macular Degeneration, Dry, Primary Open-angle Glaucoma
Retinal Photoreceptor Outer Segment Length Before and After Light Stimulation - a Pilot Study
It has been shown that reactions of human retinal photoreceptors to a light stimulus can be measured with custom-made, research prototype optical coherence tomography (OCT) systems.
- Trial name
- NCT03921931
- Testing
- White light stimulation
- Where
- Austria
- Volunteers
- 35 people, healthy volunteers welcome
- Sponsor
- Medical University of Vienna
Subjects With Primary Open-angle Glaucoma (POAG)
Prospective Evaluation of Open-Angle Glaucoma Subjects on One Topical Hypotensive Medication Treated With Two iStents
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of two iStent devices in eyes of subjects with primary open-angle glaucoma
- Trial name
- NCT01252862
- Testing
- iStent
- Where
- Armenia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Glaukos Corporation
Open Angle Glaucoma, Primary Open Angle Glaucoma
Safety and Effectiveness of the Hydrus Microstent
The purpose of this study is to assess the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in pseudophakic patients with open-angle glaucoma for whom IOP is not sufficiently controlled on…
- Conditions
- Open Angle Glaucoma, Primary Open Angle Glaucoma, Pseudoexfoliation Glaucoma, Pigmentary Glaucoma
- Trial name
- FRONTIER (NCT05198297)
- Testing
- Hydrus Microstent, Ophthalmic surgery
- Where
- 5 sites in United States
- Volunteers
- 33 people
- Sponsor
- Alcon Research
Ocular Hypertension, Glaucoma, Open-Angle
Efficacy And Safety Of Xalatan Compared To Usual Care In Patients With Open Angle Glaucoma Or Ocular Hypertension.
The primary purpose is to compare the intraocular pressure reducing effect of Xalatan with that of usual care over 36 months. Safety and health care utilization will be evaluated.
- Trial name
- NCT00140062
- Testing
- latanoprost 0.005% (Xalatan)
- Where
- 27 sites in Finland, Sweden
- Volunteers
- 329 people
- Sponsor
- Pfizer